Prelude Therapeutics IncNASDAQ:PRLD
- LAST PRICE4.0700
- TODAY'S CHANGE (%)0.0300 (0.7426%)
- Bid / Lots3.8500/ 1
- Ask / Lots4.4800/ 2
- Open / Previous Close4.0500 / 4.0400
- Day Range
- 52 Week Range
- Volume18,553
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRLD |
|---|---|---|
| 09:41 ET | 100 | 4.05 |
| 10:03 ET | 600 | 4.0038 |
| 10:28 ET | 100 | 3.99 |
| 11:20 ET | 1525 | 3.99 |
| 11:36 ET | 6445 | 4 |
| 12:23 ET | 100 | 4 |
| 01:15 ET | 640 | 4.035 |
| 02:02 ET | 100 | 4.01 |
| 02:04 ET | 200 | 4 |
| 03:50 ET | 200 | 4 |
| 03:56 ET | 200 | 4.01 |
| 03:59 ET | 221 | 4.07 |
Apr 9, 2024
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting, from 4:35PM ET on Tuesday Apr 09, 2024 by Dow Jones
4:35PM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prelude Therapeutics Inc | 223.5M | -2.0x | --- |
Renovaro Inc | 219.8M | -2.2x | --- |
Ovid Therapeutics Inc | 219.2M | -4.2x | --- |
Aldeyra Therapeutics Inc | 231.5M | -6.2x | --- |
Merrimack Pharmaceuticals Inc | 214.1M | -178.4x | --- |
Galectin Therapeutics Inc | 213.6M | -4.6x | --- |
Company Information
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Contact Information
- Headquarters
- 175 Innovation BoulevardWILMINGTON, DE, United States 19805
- Phone
- 302-467-1280
- Fax
- 302-658-3989
Executives
- Independent Chairman of the Board
- Paul Friedman
- President, Chief Medical Officer
- Jane Huang
- Chief Executive Officer, Founder, Director
- Krishna Vaddi
- Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary
- Bryant Lim
- Executive Vice President, Head of Chemistry
- Andrew Combs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $223.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-2.05 |
Book Value | $4.32 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
